CXCL9 and ovarian serous adenocarcinoma: Moreover, a recent study by Terzic et al. might further corroborate our rationale of Cxcl9 driving ICB since it reported a sustained response to first-line pembrolizumab monotherapy in a case of CSMD3-mutated high-grade serous ovarian cancer that is characterised by a strong upregulation of CXCL9 [39].